Researchers developed a PRESTO tool using clinical variables to predict PsA risk in PsO patients with reasonable accuracy.

Roflumilast showed significant improvement in disease severity in 95% of plaque psoriasis patients by week 8.

Psoriasis is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. These findings come from a study...

Patients who have contracted Covid-19 may have a higher risk of developing psoriasis and other immune-mediated inflammatory diseases.

Findings from a cross-sectional study of survey data suggest that U.S. sexual and gender minority (SGM) patients with chronic...

Dr. Vimal Prajapati reports on late breaking psoriasis developments from the 2023 EADV Congress in Berlin.

Dr. Mark Kirchoff reports lives from the 2023 EADV Congress in Berlin and gives insights into the pathogenesis of psoriasis.

Risankizumab is effective at achieving skin clearance in moderate-to-severe plaque psoriasis in bio-naive patients.